千金药业2025年净利2.88亿元，同比增长24.74%

Core Viewpoint - Qianjin Pharmaceutical (600479) reported a slight increase in revenue and a significant rise in net profit for the year 2025, indicating stable performance and growth potential in the pharmaceutical sector [1] Financial Performance - The company achieved an operating revenue of 3.635 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders reached 288 million yuan, showing a year-on-year increase of 24.74% [1] Growth Drivers - The growth in performance is primarily attributed to stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results as they were included in the consolidated financial statements starting from October and November 2025, respectively [1]